Kobiolabs is a pioneering company in the field of microbiome therapeutics, focusing on the development of innovative treatments that leverage the complex interactions between the human microbiome and various health conditions. The company emphasizes the significance of the microbiome, which consists of trillions of microorganisms residing in the human body, in regulating immune responses, metabolism, and neurological functions. By harnessing this knowledge, Kobiolabs aims to create effective therapies targeting diseases related to immunity, metabolism, and central nervous system disorders.

Central to Kobiolabs' approach is their Smartiome platform, which utilizes AI-driven multi-omics analysis and a comprehensive microbial library to facilitate drug development. This platform embodies the concept of "Human Data to Human Drug," enabling the translation of microbiome research into practical therapeutic solutions. Additionally, Kobiolabs employs a Microbe-Based Drug Delivery System (mDDS) to enhance the efficacy of their treatments, showcasing their commitment to integrating cutting-edge technology with microbiome science to improve human health outcomes.

South Korea

KoBioLabs is recognized for its international level of microbiome therapeutic technologies.
In particular, our researchers have a distinctive position in the microbiology field globally
with their presence in the ongoing International Human Microbiome Consortium [IHMC].

Kobiolabs

Company Details